Thiourea inhibitors of herpesviruses. Part 3: Inhibitors of varicella zoster virus

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 16, 2004, Pages 4157-4160

  Di Grandi, Martin J ^a   Curran, Kevin J ^a   Feigelson, Gregg ^a   Prashad, Amar ^a   Ross, Adma A ^a   Visalli, Robert ^a,b   Fairhurst, Jeanette ^a   Feld, Boris ^a   Bloom, Jonathan D ^a  

^a WYETH RESEARCH   (United States)

^b PURDUE UNIVERSITY FORT WAYNE   (United States)

Author keywords

Inhibitors; Novel inhibitors; Thiourea; Varicella zoster virus; VZV

Indexed keywords

ANTIVIRUS AGENT; NUCLEOSIDE; THIOUREA DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HERPES VIRUS; IC 50; NONHUMAN; STRUCTURE ACTIVITY RELATION; VARICELLA ZOSTER VIRUS; VIRUS INHIBITION;

ANTIVIRAL AGENTS; HERPESVIRUS 3, HUMAN; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA;

HUMAN HERPESVIRUS 3;

EID: 3142737987     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.06.025     Document Type: Article

References (11)

1. Kennedy P.G.E. Rev. Med. Virol. 12:2002;327-334
2. Snoeck R., Andrei G., De Clerq E. Expert. Opin. Invest. Drugs. 9:2000;1743-1751
3. Bloom J.D., Di Grandi M.J., Dushin R.G., Curran K.J., Ross A.A., Norton E.B., Terefenko E., Jones T.R., Feld B., Lang S.A. Bioorg. Med. Chem. Lett. 13:2003;2929-2932
4. Bloom J.D., Dushin R.G., Curran K.J., Donahue F., Norton E.B., Terefenko E., Jones T.R., Ross A.R., Feld B., Lang S.A., Di Grandi M.J. Bioorg. Med. Chem. Lett. 14:2004;3401-3406
5. Visalli R.J., Fairhurst J., Srinivas S., Hu W., Feld B., Di Grandi M.J., Curran K., Ross A., Bloom J.D., Van Zeijl M., Jones T.R., O'Connell J., Cohen J.I. J. Virology. 77:2003;2349-2358
6. Van Zeijl M., Fairhurst J., Jones T.R., Vernon S.K., Morin J., LaRocque J., Feld B., O'Hara B., Bloom J.D., Johann S.V. J. Virology. 74:2000;9054-9061
7. 50 values of >20 μM (data not shown) and were substantially less active against CMV
8. The trend shown in Table 1 held true for most analogs; in the few instances where little to no preference for either enantiomer was observed, both isomers were essentially inactive
9. In the case of our CMV inhibitors, the corresponding ureas were about 10-15 times less active; see Ref. [3a]
10. 4Cl, EtOH)
11. Baskaran S., Baskaran C., Trivedi G.K. J. Chem. Res. Synopsis. 1997;394-395. and references cited therein